Trial intelligence / Profile preview

Safety and Immunogenicity of COVID-19 Vaccination in Patients With Cancer

NCT05018078Unknown

Sponsor
The Fifth Medical Center of the PLA General Hospital
Start
Aug 2021
Primary completion
Aug 2023
Countries
1
01

Overview

Open-label, single-arm trial in coronavirus disease 2019 (COVID-19), sponsored by The Fifth Medical Center of the PLA General Hospital. Primary endpoints: Safety of coronavirus vaccine at 2 months and Immunogenicity of coronavirus vaccine at 2 months. Status: unknown.

02

Conditions

coronavirus disease 2019 (COVID-19)

Beyond the preview

Go deeper on NCT05018078.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT05018078.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call